by 
Saturday, May 7, 2022 3:45 PM – 5:45 PM ET Oregon Ballroom 201
Overcoming Current Roadblocks in CAR T Cell Therapy
Chair
- Anna Halling Folkmar Andersen, New York Univ. Langone Med. Center
Speakers
- Monika Kizerwetter, Johns Hopkins Univ., Anti-CD123 chimeric antigen receptor natural killer cell therapy to treat acute myeloid leukemia
- Nicholas R. J. Gascoigne, Natl. Univ. of Singapore, Utilizing distinct CAR and TCR signaling to generate enhanced cellular immunotherapy
- Daniel S. Wilkinson, Duke Univ. Med. Ctr., D2C7 CAR: A novel CAR T cell that simultaneously targets wildtype EGFR and its mutant isoform EGFRvIII for treatment of glioma
- Jillian Baker, Univ. of Maryland Sch. of Med., Engineering anti-CD229 CAR T cell selectivity for multiple myeloma
- Xander Gordon Ray Bradeen, Univ. of Colorado Anschutz Med. Campus, Identifying novel epigenetic modifiers that sensitize T cell malignancies to CD8+ T cell mediated cytotoxicity by high throughput drug screen
- Royce Ma, Baylor Col. of Med., T cells resist CD5 CAR mediated fratricide by continuously degrading CD5 protein
- Caitlin C. Zebley, St. Jude Children’s Res. Hosp., CD19-CAR T cells develop exhaustion epigenetic programs during a clinical response
- Nayan Jain, Mem. Sloan Kettering Cancer Ctr., SUV39H1 disruption imparts functional persistence to CD28-costimulated human CAR T cells
